What is Biofrontera?
Headquartered in Woburn, Massachusetts, Biofrontera Inc. operates as a specialized biopharmaceutical entity focused on the commercialization of advanced pharmaceutical products. The company maintains a targeted portfolio addressing critical dermatological conditions, most notably actinic keratoses—pre-cancerous skin lesions—and bacterial skin infections such as impetigo. Its flagship offering, Ameluz, represents a sophisticated approach to photodynamic therapy when utilized alongside the proprietary RhodoLED lamp series. Furthermore, the company's inclusion of Xepi, a topical non-fluorinated quinolone, demonstrates a diversified product strategy aimed at both lesion-directed and field-directed treatment modalities. Since its incorporation in 2015, Biofrontera has established a distinct market presence by bridging the gap between clinical innovation and patient-centric dermatological care in the United States.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $17.5M across 2 funding rounds:
Debt
$6.5M
Stock/Share Issuance
$11M
Debt (2023): $6.5M with participation from MidCap Business Credit
Stock/Share Issuance (2025): $11M, investors not publicly disclosed
Key Investors in Biofrontera
MidCap Business Credit
MidCap Business Credit LLC is an independent commercial finance company which provides asset based loans for companies unable to obtain traditional bank financing.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Biofrontera?
With the recent infusion of $11M, Biofrontera is expected to prioritize the expansion of its commercial footprint and the optimization of its therapeutic delivery systems. The transition from debt-based instruments, such as the 2023 financing provided by MidCap Business Credit, to the current equity-focused capital structure suggests a strategic pivot toward scaling operations and enhancing market penetration. Future initiatives will likely involve deepening the adoption of the Ameluz-RhodoLED combination therapy among dermatologists, while simultaneously exploring potential pipeline enhancements to address broader skin health indications. As the company matures, this financial backing serves as a critical catalyst for sustaining long-term growth and maintaining its competitive edge in the high-barrier-to-entry biopharmaceutical sector.
See full Biofrontera company page
